Impact BioMedical, INC. (IBO) Spending and interest coverage
- R&D / revenue · 12 months: Value 814.29%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 4140.00%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 814.29% | Research and development expense / revenue. Period ending 2026-06-30. $285.00K ÷ $35.00K × 100 ≈ 814.29% |
| Stock-based compensation / revenue · 12 months | 4140.00% | Share-based compensation / revenue. Period ending 2026-06-30. $1.45M ÷ $35.00K × 100 ≈ 4140.00% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 285.00K USD | Research and Development Expense |
| Revenue | 35.00K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 1.45M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -5.11M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $285.00K | $35.00K | $1.45M | $-5.11M | (m) | 814.29% | 4140.00% | (m) | (m) |
| 2026-03-31 | $283.00K | $39.00K | $1.45M | $-5.56M | (m) | 725.64% | 3720.51% | (m) | (m) |
| 2025-12-31 | $340.00K | $32.00K | $13.00K | $-4.28M | $793.00K | 1062.50% | 40.63% | -5.40× | Reported |
| 2025-09-30 | $122.00K | (m) | (m) | $-29.34M | $1.06M | (m) | (m) | -27.60× | Reported |
| 2025-06-30 | $152.00K | (m) | (m) | $-29.52M | $1.10M | (m) | (m) | -26.72× | Reported |
| 2025-03-31 | $198.00K | (m) | (m) | $-28.99M | $1.11M | (m) | (m) | -26.21× | Reported |
| 2024-12-31 | $278.00K | (m) | $19.00K | $-28.75M | $1.06M | (m) | (m) | -27.00× | Reported |
| 2024-09-30 | $478.00K | (m) | (m) | $-3.66M | $920.00K | (m) | (m) | -3.98× | Reported |
| 2024-06-30 | $752.00K | (m) | (m) | $-3.61M | $718.00K | (m) | (m) | -5.03× | Reported |
| 2024-03-31 | $1.02M | (m) | (m) | $-4.00M | $573.00K | (m) | (m) | -6.97× | Reported |
| 2023-12-31 | $1.15M | (m) | (m) | $-4.03M | $444.00K | (m) | (m) | -9.07× | Reported |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $1.23M | $50.00K | (m) | $-3.40M | $462.00K | 2452.00% | (m) | -7.37× | Reported |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |